OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer
7. The period between diagnosis and enrollment does not exceed 8 weeks;
8. Be willing to provide blood samples for OCS testing during the research process;
9. Sign the informed consent form.
You may not be if
1. Have had other malignant tumors within the last five years;
2. Have received any treatment for ovarian cancer;
3. Benign ovarian mass;
4. Non-primary ovarian tumors;
5. Combined with other malignant tumors;
6. Patients receiving neoadjuvant therapy;
7. Pregnancy.
Clareo Health | OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer
